Everything below concerns thymosin beta-4. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-10-13. Numbers and descriptions here follow the published literature rather than marketing material.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Pin-point pupils may occur. Patient presenting with dilated pupils may still be experiencing an opioid overdose. Decreased heart rate Decreased body temperature Decreased breathing Altered level of consciousness. People may be unresponsive or unconscious. Pulmonary edema (fluid accumulation in the lungs) Shock Death
=== Legal status === For follicular lymphoma, the U.S. Food and Drug Administration (FDA) awarded copanlisib orphan drug designation in February 2015, and fast track designation in February 2016. The New drug application for follicular lymphoma was granted priority review in May 2017. In September 2017, it received accelerated approval for the treatment of adults experiencing relapsed follicular lymphoma who have received at least two prior systemic therapies. Further clinical trials are to be performed as a post-marketing requirement to verify the clinical benefit. Copanlisib was granted orphan drug status for the treatment of splenic, nodal and extranodal subtypes of marginal zone lymphoma.
=== Story === The player follows Angela's journey toward the "one perfect book" in the Library from the view of Roland, a Fixer who becomes her servant after trespassing into the Library uninvited. The story is broken up into various chapters. As Roland's past is gradually shed light on and Angela comes closer to becoming human, the Library becomes an ever-growing threat to the City, urging the Associations (organized groups of fixers, often centered around a single theme) to take action. Argalia, a mysterious Fixer known as the "Blue Reverberation" recruits various characters into a group known as the "Reverberation Ensemble" for an unknown cause, culminating in them breaking into the Library, scattering to the ten floors to claim the Light for their greatest performance that will overturn the City. The Library ultimately emerges victorious after a hard-fought battle. Just as Angela finally gains a human body, Roland betrays Angela and reveals his true motive for coming to the Library: to make her suffer as revenge for her actions instigating the Distortion phenomenon and indirectly causing the death of his wife Angelica, a former Color Fixer known as the "Black Silence". Roland ultimately fails to defeat the Library and pleads for Angela to kill him, or he will kill her if she falters. If all of Angela's Floor realizations have not been completed, she will kill Roland and the Librarians and obtain the one true book.
What has come to be called the "clinical versus statistical prediction" debate was first described in detail in 1954 by Paul Meehl, where he explored the claim that mechanical (formal, algorithmic) methods of data combination could outperform clinical (e.g., subjective, informal, "in the clinician's head") methods when such combinations are used to arrive at a prediction of behavior. Meehl concluded that mechanical modes of combination performed as well or better than clinical modes. Subsequent meta-analyses of studies that directly compare mechanical and clinical predictions have borne out Meehl's 1954 conclusions. A 2009 survey of practicing clinical psychologists found that clinicians almost exclusively use their clinical judgment to make behavioral predictions for their patients, including diagnosis and prognosis.
The use of electron cyclotron resonance (ECR) ion sources for the production of intense beams of highly charged ions has immensely grown over the last decade. ECR ion sources are used as injectors into linear accelerators, Van-de-Graaff generators or cyclotrons in nuclear and elementary particle physics. In atomic and surface physics ECR ion sources deliver intense beams of highly charged ions for collision experiments or for the investigation of surfaces. For the highest charge states, however, Electron beam ion sources (EBIS) are needed. They can generate even bare ions of mid-heavy elements. The Electron beam ion trap (EBIT), based on the same principle, can produce up to bare uranium ions and can be used as an ion source as well.
Sources: en.wikipedia.org
=== Constituents === Nutmeg consists of 25 to 40% fatty oils or triglycerides (nutmeg butter), 7 to 16% volatile oils, and 45 to 60% pulp or structural components like cellulose. The triglyceride part is mostly trimyristin, but triolein and trilinolein are also found in small amounts. The psychoactive component of nutmeg appears to be the volatile oil component, with most of the rest inactive in animals and humans. It consists 80% of a terpene fraction, 10 to 15% of an aromatic fraction, and the small remainder fatty acids. Turpentine, a fluid made from the resin mainly of pine trees, has a similar composition as the terpene fraction of nutmeg, but has no reputation for producing intoxicating effects. The aromatic fraction of nutmeg consists of a number of allylbenzenes (propenylbenzenes), mainly myristicin, elemicin, and safrole (these three 84–95%), but also including methyleugenol, methylisoeugenol, methoxyeugenol, isoeugenol, eugenol, and isoelemicin. A 20 gram amount of nutmeg contains about 210 mg myristicin, 70 elemicin, 39 mg safrole, as well as 3 to 18 mg each of the other compounds. Myristicin makes up approximately 1.3% of whole nutmeg and about 4 to 13% of the volatile oil fraction. Myristicin and elemicin have been thought to be nutmeg's psychoactive constituents, whereas safrole and the various eugenols seem to be inactive with regard to such effects. Though other nutmeg components are inactive, they might aid in the absorption of the active constituents.
== Death == Sun likely spent the last few years of his life as a monk, before working as a caretaker of the Guanghua temple in Beijing. He lived there until his death on 17 December 1996 at the age of 93.
==== High-performance liquid chromatography ==== Many forms of chromatography, including high-performance liquid chromatography (HPLC), nanoflow ultra-performance liquid chromatography (nano-UPLC or nano-LC), and 2-dimensional capillary flow chromatography (capillary LC), have been integrated into the field of droplet-based microfluidics. On the microscale, chemical separation techniques like HPLC can be used in both biological and chemical analysis. Within the field of microfluidics, these techniques have been applied to microfluidic systems at three different stages in the microfluidic process. Off-chip HPLC columns are used to separate analytes before feeding them into a microfluidic device for fractionation and analysis. HPLC columns can also be built directly into microfluidic lab-chips creating monolithic hybrid devices capable of chemical separation as well as droplet formation and manipulation. Additionally, HPLC is used at the tail end of droplet-based microfluidic chemistry as a way to purify, analyze, and quantify the products of an experiment. Droplet-based microfluidic devices coupled to HPLC have high detection sensitivity, use low volumes of reagents, have short analysis times, and minimal cross-contamination of analytes, which make them efficient in many aspects. However, there are still problems associated with microscale chromatography, such as dispersion of separated bands, diffusion, and "dead volume" in channels after separation.
Moreover, although it has been established that ethanol modulates ion channels to mediate its effects, ion channels are complex proteins, and their interactions and functions are complicated by diverse subunit compositions and regulation by conserved cellular signals (e.g. signaling lipids). Alcohol is also converted into phosphatidylethanol (PEth, an unnatural lipid metabolite) by phospholipase D2. This metabolite competes with PIP2 agonist sites on lipid-gated ion channels. The result of these direct effects is a wave of further indirect effects involving a variety of other neurotransmitter and neuropeptide systems. This presents a novel indirect mechanism and suggests that a metabolite, not the ethanol itself, could cause the behavioural or symptomatic effects of alcohol intoxication. Many of the primary targets of ethanol are known to bind PIP2 including GABAA receptors, but the role of PEth needs to be investigated further.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.